Takeda has reported strong phase 3 results for its drug Zasocitinib in treating plaque psoriasis. The results show Zasocitinib outperforming other treatments, including Deucravacitinib, in head-to-head studies. The positive results may pave the way for FDA approval, with some reports suggesting a potential approval as early as 2026.